全球癌症單株抗體市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計癌症單株抗體市場將從 2025 年的 1,318.5 億美元成長到 2034 年的 6,247.9 億美元，2026 年至 2034 年的複合年成長率為 18.87%。

由於癌症發病率的上升和對標靶治療需求的日益成長，癌症單株抗體市場正經歷顯著成長。單株抗體（mAb）是人工合成的蛋白質，旨在特異性靶向癌細胞，與傳統化療相比，它提供了更精準的治療選擇。隨著醫療機構和患者尋求更有效、毒性更小的治療方法方案，對癌症單株抗體的需求預計將會增加，從而推動該市場的強勁成長。目前的治療方法包括曲妥珠單抗和Rituximab等已上市的單株抗體，以及針對各種癌症類型的新型藥物。

此外，單株抗體技術的進步正在推動市場創新。雙特異性抗體、抗體藥物複合體和免疫查核點抑制劑的研發，透過提高治療的療效和特異性，正在革新癌症治療。這些創新不僅改善了治療效果，還最大限度地減少了副作用，並提高了患者的整體生活品質。隨著單株抗體新應用和聯合治療的研究不斷深入，預計隨著更多治療方案的出現，市場將進一步擴張。

此外，對個人化醫療的日益重視正在重塑癌症單株抗體領域。隨著醫療服務提供者越來越認知到根據患者的基因和分子特徵量身定做治療方案的重要性，對符合個人化治療策略的單株抗體（mAb）的需求預計將會成長。這一趨勢在伴隨診斷領域尤其重要，因為特定的生物標記可以指導選擇合適的單株抗體療法。隨著癌症單株抗體市場的不斷發展，創新治療方法組合、對個人化醫療的關注以及持續的研究將在推動未來成長方面發揮關鍵作用。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

第4章 全球癌症單株抗體市場（按類型分類）

• 市場分析、洞察與預測
• 人源化單株抗體
• 人類
• 嵌合體
• 小鼠來源

第5章 全球癌症單株抗體市場（依應用分類）

• 市場分析、洞察與預測
• 血癌
• 乳癌
• 肺癌
• 黑色素瘤
• 大腸直腸癌
• 肝癌
• 其他

第6章 全球癌症單株抗體市場（依最終用戶分類）

• 市場分析、洞察與預測
• 醫院
• 研究所
• 其他

7. 全球癌症單株抗體市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche Ltd
  • Bristol Myers Squibb Co
  • Merck & Co
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Amgen Inc
  • Novartis AG
  • AstraZeneca Plc
  • Eli Lilly And Company
  • AbbVie

The Cancer Monoclonal Antibodies Market size is expected to reach USD 624.79 Billion in 2034 from USD 131.85 Billion (2025) growing at a CAGR of 18.87% during 2026-2034.

The cancer monoclonal antibodies market is experiencing significant growth, driven by the increasing prevalence of cancer and the rising demand for targeted therapies. Monoclonal antibodies (mAbs) are engineered proteins designed to specifically target cancer cells, offering a more precise treatment option compared to traditional chemotherapy. As healthcare providers and patients seek effective and less toxic treatment alternatives, the demand for cancer monoclonal antibodies is expected to rise, positioning this market for robust expansion. Current therapies include well-established mAbs such as trastuzumab and rituximab, as well as newer agents that target various cancer types.

Moreover, advancements in monoclonal antibody technology are propelling innovation within the market. The development of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors is revolutionizing cancer treatment by enhancing the efficacy and specificity of therapies. These innovations not only improve treatment outcomes but also minimize side effects, thereby improving the overall quality of life for patients. As research continues to explore new applications and combinations of monoclonal antibodies, the market is likely to expand further, driven by the promise of improved therapeutic options.

Additionally, the growing emphasis on personalized medicine is shaping the cancer monoclonal antibodies landscape. As healthcare providers increasingly recognize the importance of tailoring treatments to individual patient profiles based on genetic and molecular characteristics, the demand for mAbs that align with personalized treatment strategies is likely to rise. This trend is particularly relevant in the context of companion diagnostics, where specific biomarkers guide the selection of appropriate monoclonal antibody therapies. As the cancer monoclonal antibodies market continues to evolve, the combination of innovative therapies, a focus on personalized care, and ongoing research will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Humanized
• Human
• Chimeric
• Murine

By Application

• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others

By End-user

• Hospitals
• Research Institutes
• Others

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, Bristol Myers Squibb Co, Merck Co, GlaxoSmithKline plc, Johnson Johnson, Amgen Inc, Novartis AG, AstraZeneca plc, Eli Lilly and Company, AbbVie

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Murine Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Application
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Application
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Application
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Application
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Application
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER MONOCLONAL ANTIBODIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 F. Hoffmann-La Roche Ltd
  • 9.2.2 Bristol Myers Squibb Co
  • 9.2.3 Merck & Co
  • 9.2.4 GlaxoSmithKline Plc
  • 9.2.5 Johnson & Johnson
  • 9.2.6 Amgen Inc
  • 9.2.7 Novartis AG
  • 9.2.8 AstraZeneca Plc
  • 9.2.9 Eli Lilly And Company
  • 9.2.10 AbbVie